We recently described that the malignant progression of CCA-like lesions in DEN/CCl4 treated Jnk∆hepa mice can be inhibited by the administration of CM272, a novel epigenetic drug that simultaneously targets the histone methyltransferase G9a and DNA-methyltransferase 1 (DNMT1) [17]. Here, PRDM9 is linked to cholangiocarcinoma.